Morganella morganii explained
Morganella morganii is a species of Gram-negative bacteria.[1] It has a commensal relationship within the intestinal tracts of humans, mammals, and reptiles as normal flora.[1] Although M. morganii has a wide distribution, it is considered an uncommon cause of community-acquired infection, and it is most often encountered in postoperative and other nosocomial infections, such as urinary tract infections.[2]
Historical identification and systematics
Morganella morganii was first described by a British bacteriologist H. de R. Morgan in 1906 as Morgan's bacillus. Morgan isolated the bacterium from stools of infants who were noted to have had "summer diarrhea".[3] Later in 1919, Winslow et al. named Morgan's bacillus, Bacillus morganii. In 1936, though, Rauss renamed B. morganii as Proteus morganii. Fulton, in 1943, showed that B. columbensis and P. morganii were the same and defined the genus Morganella, due to the DNA–DNA hybridization.[4] In 1943, Fulton attempted to define a subspecies, M. m. columbensis.[5] However, in 1962, a review article by Ewing reported that M. columbensis had been re-identified as Escherichia coli, thereby removing that organism from the genus Morganella.
Microbiology
Morganella morganii is facultatively anaerobic and oxidase-negative. Its colonies appear off-white and opaque in color, when grown on agar plates.[6] M. morganii cells are straight rods, about 0.6–0.7 μm in diameter and 1.0–1.7 μm in length. This organism moves by way of peritrichous flagella, but some strains do not form flagella at 30C.[7]
M. morganii is split into two subspecies: M. morganii subsp. morganii and M. morganii subsp. sibonii. M. morganii subsp. sibonii is able to ferment trehalose, whereas subsp. morganii cannot, and this is the primary phenotype used to differentiate them.
M. morganii can produce the enzyme catalase, so it is able to convert hydrogen peroxide to water and oxygen. This is a common enzyme found in most living organisms. In addition, it is indole test-positive, meaning that this organism can split tryptophan to indole, pyruvate, and ammonia. M. morganii also produces urease, allowing it to break down urea.[8] Methyl red tests positive in M. morganii, an indicator dye that turns red due to the bacterium's acid production during fermentation. Similar bacteria from the closely related Proteus and Providencia genera, M. morganii is able to deaminate tryptophan through the production of tryptophan deaminase (TDA).
Role of bacteria
Although a rare human pathogen, M. morganii has been reported as a cause of urinary tract infections, nosocomial surgical wound infections, peritonitis, central nervous system infection, endophthalmitis, pneumonia, chorioamnionitis, neonatal sepsis, pyomyositis, necrotizing fasciitis, and arthritis. Numerous cases of nosocomial infection have been described, usually as postsurgical wound infections or urinary tract infections. Patients in whom bacteremia develops are typically immunocompromised, diabetic, or elderly, or have at least one serious underlying disease.M. morganii has been regarded as a normally harmless opportunistic pathogen, but some strains carry "antibiotic-resistant plasmids" and have been associated with nosocomial outbreaks of infections.[9] Several reports indicate M. morganii causes sepsis, ecthyma, endophthalmitis, and chorioamnionitis, and more commonly urinary tract infections, soft tissue infections, septic arthritis, meningitis, and bacteremia, in the latter 2 cases with frequent fatal consequences.[10]
In a rare case published in 2003, a patient presented with bilateral necrosis of both upper and lower eyelids. Upon microbial analysis, the areas were shown to have heavy growth of M. morganii.[11]
Treatment and antibiotic resistance
Treatment of M. morganii infections may include:
A study conducted at the University Hospital at Heraklion, Crete, Greece, showed a 92% success rate in the use of these antibiotics.[12]
However, some M. morganii strains are resistant to penicillin, ampicillin/sulbactam, oxacillin, first-generation and second-generation cephalosporins, macrolides, lincosamides, fosfomycin, colistin, and polymyxin B. The emergence of highly resistant strains of M. morganii have been associated with use of third-generation cephalosporins.
Polymicrobial infections are most abundantly caused by this microbe which additionally damages the skin, soft tissues, and urogenital tract; these can be cured through use of the aforementioned antibiotics.
Further reading
- De . A . Raj . HJ . Maiti . PK . 2016 . Biofilm in osteomyelitis caused by a rare pathogen, Morganella morganii: A case report . Journal of Clinical and Diagnostic Research . 10 . 6 . DD06–DD08 . 10.7860/JCDR/2016/18666.7990 . 27504288 . . 4963648.
- Emborg . J . Dalgaard . P . 2008 . Growth, inactivation and histamine formation of Morganella psychrotolerans and Morganella morganii - development and evaluation of predictive models . . 128 . 2 . 234–243 . 10.1016/j.ijfoodmicro.2008.08.015 . 18845350 . Elsevier Science Direct.
- Hu . LT . Nicholson . EB . Jones . BD . Lynch . MJ . Mobley . HLT . 1990 . Morganella morganii urease: Purification, characterization, and isolation of gene sequences . . 172 . 6 . 3073–3080 . 10.1128/jb.172.6.3073-3080.1990 . 2345135 . Elsevier Science Direct . 209110.
- Lee. IK. Liu. JW. 2006. Clinical characteristics and risk factors for mortality in Morganella morganii bacteremia. Journal of Microbiology, Immunology, and Infection. 39. 4 . 328–334. 16926980 . Elsevier Science Direct.
- Liu. H. Zhu. J. Hu. Q. Rao. X. 2016. Clinical characteristics and risk factors for mortality in Morganella morganii bacteremia. International Journal of Infectious Diseases. 50. 10–17. 10.1016/j.ijid.2016.07.006. 27421818. Elsevier Science Direct. free.
- Özoğul. F. 2004. Production of biogenic amines by Morganella morganii, Klebsíella pneumoniae and Hafnia alvei using a rapid HPLC method. European Food Research and Technology. 219. 5. 465–469. 10.1007/s00217-004-0988-0. 84860663. Elsevier Science Direct.
- Parikh . RY . Ramanathan . R . Coloe . PJ . Bhargava . SK . Patole . MS . Shouche . YS . Bansal . V . 2011 . Genus-wide physicochemical evidence of extracellular crystalline silver nanoparticles biosynthesis by morganella spp . . 6 . 6 . e21401 . 10.1371/journal.pone.0021401 . 21713008 . Elsevier Science Direct . 3119697. 2011PLoSO...621401P . free .
- Rojas . L . Vinuesa . T . Tubau . F . Truchero . C . Benz . R . Viñas . M . 2006 . Integron presence in a multiresistant Morganella morganii isolate . . 27 . 6 . 502–512 . 10.1016/j.ijantimicag.2006.01.006 . 16690260 . Elsevier Science Direct. Stock. I. Wiedemann. B. 1998. Identification and natural antibiotic susceptibility of Morganella morganii. Diagnostic Microbiology and Infectious Disease. 30. 3. 153–165. 10.1016/S0732-8893(97)00243-5. 9572021. Elsevier Science Direct.
External links
Notes and References
- eMedicine. Morganella infections
- Web site: Morganella infections . 5 December 2012 . Medscape.
- Pulaski. E. J.. Deitz. G. W.. Morgan's bacillus septicemia . Journal of the American Medical Association. 115. 11. 1940. 922. 0002-9955. 10.1001/jama.1940.72810370001008.
- Chen . Yu-Tin . Peng . Hwei-Ling . Shia . Wei-Chung . Hsu . Fang-Rong . Ken . Chuian-Fu . Tsao . Yu-Ming . Chen . Chang-Hua . Liu . Chun-Eng . Hsieh . Ming-Feng . Chen . Huang-Chi . Tang . Chuan-Yi . 2012 . Whole-genome sequencing and identification of Morganella morganii KT pathogenicity-related genes . . 13 . Suppl 7 . S4 . 10.1186/1471-2164-13-S7-S4 . 1471-2164 . 3521468 . 23282187 . Ku . Tien-Hsiung . free .
- O'Hara CM, Brenner FW, Miller JM . 13 October 2000 . Classification, identification, and clinical significance of Proteus, Providencia, and Morganella. . . 4 . 13 . 4 . 534–546 . 10.1128/cmr.13.4.534-546.2000 . 88947 . 11023955.
- Web site: Herrara . Jose . Morganella morganii . dead . https://web.archive.org/web/20121213022138/http://jherrera.sites.truman.edu/morganella-morganii/ . 13 December 2012 . 6 December 2012 . Truman State University Biology . Truman State University.
- Web site: Morganella morganii . 6 December 2012 . University of Windsor.
- Hu . L T . Nicholson . E B . Jones . BD . Lynch . MJ . Mobley . HL . June 1990 . Morganella morganii urease: purification, characterization, and isolation of gene sequences . J Bacteriol . 172 . 6 . 3073–80 . 10.1128/jb.172.6.3073-3080.1990 . 2345135 . 209110 .
- Senior . W . S. Voros . 1990 . Protein profile typing--a new method of typing Morganella morganii strains . dead . . 33 . 4 . 259–264 . 10.1099/00222615-33-4-259 . 1701835 . https://web.archive.org/web/20110904221525/http://jmm.sgmjournals.org/content/33/4/259.full.pdf . 4 September 2011 . 6 December 2012.
- Singla . Nidhi . Neelam Kaistha . Neelam Gulati . Jagdish Chander . Jul–Sep 2010 . Morganella morganii could be an important intensive care unit pathogen . . 14 . 3 . 154–155 . 10.4103/0972-5229.74176 . 3021833 . 21253351 . free .
- Shenoy MD. AU Shenoy. AM Rajay. ZH al Mahrooqui. Necrotic Periorbital Ulceration due to Morganella morganii. Asian Journal of Ophthalmology. 2003. 5. 1. 10 December 2012. https://web.archive.org/web/20140202094202/http://www.apglaucomasociety.org/toc/v5n1/v5n1p13.pdf. 2 February 2014. dead.
- Falagas. M.E. . P.K. Kavvadia . E. Mantadakis . D.P. Kofteridis . I.A. Bliziotis . E. Saloustros . S. Maraki . G. Samonis. Morganella morganii infections in General Tertiary Hospital. Clinical and Epidemiology Study. 2006. 34. 6 . 315–321. 10.1007/s15010-006-6682-3. 17180585 . 6599259 .